

Claims

We claim:

1. An isolated antibody, wherein the antibody binds a 5' cysteine rich region of an EBA-175 protein from a *Plasmodium* species.
2. The isolated antibody of Claim 1, wherein the 5' cysteine rich region is a region II.
3. The isolated antibody of Claim 1, wherein the 5' cysteine rich region is a region II/F2.
4. The isolated antibody of Claim 1, wherein the region consists of an approximately 10 amino acid sequence.
5. The isolated antibody of Claim 4, wherein the amino acid sequence is shown in SEQ ID NO:1.
6. The isolated antibody of Claim 1, wherein the *P.* species is *Plasmodium falciparum*.
7. The isolated antibody of Claim 1, wherein the antibody inhibits binding of an EBA-175 protein to a red blood cell.
8. The isolated antibody of Claim 1, wherein the antibody inhibits *Plasmodium falciparum* invasion into a red blood cell.
9. The isolated antibody of Claim 8, wherein the antibody inhibits *Plasmodium falciparum* invasion of a red blood cell *in vitro*.
10. The isolated antibody of Claim 8, wherein the antibody inhibits *Plasmodium falciparum* invasion of a red blood cell *in vivo*.
11. The isolated antibody of Claim 1, wherein the antibody is monoclonal.

12. A hybridoma producing the monoclonal antibody of Claim 11.

5 13. A method of treating a *Plasmodium* species related disease comprising, administering to an individual the isolated antibody of Claim 1 in an amount effective to treat the *Plasmodium* species related disease.

14. The method of Claim 13, wherein the *Plasmodium* species is *Plasmodium falciparum*.

15. The method of Claim 14, wherein the *Plasmodium falciparum* related disease is malaria.

16. A method of inhibiting *Plasmodium falciparum* invasion into a red blood cell of an individual comprising, administering to the individual the isolated antibody of Claim 1 in an amount effective to inhibit *Plasmodium falciparum* invasion into the red blood cell.